Three novel nonsteroidal antiandrogen agents for treating high - risk nmCRPC have been investigated; the PROSPER, SPARTAN and ARAMIS trials were phase III, randomized, placebo - controlled clinical trials that investigated the efficacy and safety of enzalutamide, apalutamide and darolutamide, respectively.